EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Nai Lee, Yun Kim iD

Diabetes/Metabolism Research and Reviews · 2026-05 · 42 (4)

DOI: 10.1002/dmrr.70163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 26.03.2026. Verfasst von Nai Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Daegu Catholic University, Gyeongsan, Gyeongsangbuk-do, South Korea. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Alopecia, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Catholic University of Daegu, Gyeongsangbuk-do RISE Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance database. Materials and Methods This study analysed the U.S. FDA Adverse Event Reporting System (FAERS) data (Q2 2022–Q2 2025) for six GLP‐1 Ras (exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide) to identify alopecia‐ and reproductive or endocrine–related a AEs. Disproportionality analyses were conducted using crude and adjusted reporting odds ratios (cROR and aROR) from logistic regression controlling for potential confounding factors. Sensitivity analyses with positive and negative controls were used to validate the signal robustness.

Results

A total of 1276 alopecia‐related and 759 reproductive or endocrine–related cases were identified. Semaglutide showed significant positive associations with alopecia (aROR 1.23 [1.11–1.35]) and reproductive/hormonal disorders, including polycystic ovary syndrome (aROR 6.59 [3.73–11.64]) and menstrual abnormalities. In contrast, dulaglutide and tirzepatide demonstrated negative associations for several reproductive outcomes (e.g., dysmenorrhoea, amenorrhoea, heavy menstrual bleeding), indicating lower reporting odds in this dataset. Sensitivity analyses using control drugs confirmed the consistency and specificity of these findings.

Conclusion

This real‐world pharmacovigilance study identified agent‐specific differences in the endocrine and dermatologic safety profiles of GLP‐1 RAs. While semaglutide exhibited disproportionate reporting for alopecia and hormonal imbalance, dulaglutide and tirzepatide showed lower or non‐significant disproportionality signals for these events. These results highlight the need for personalised agent selection and continued pharmacovigilance to optimise long‐term patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAlopeciaHypoglycemic AgentsDiabetes Mellitus, Type 2HumansSemaglutideFemaleTirzepatideGlucagon-Like PeptidesPharmacovigilanceUnited StatesAdverse Drug Reaction Reporting SystemsMaleExenatideLiraglutideFollow-Up StudiesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

FDA adverse event reporting systemGLP‐1 receptor agonistsalopeciareproductive or endocrine‐related adverse events

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideGlucagon-Like PeptidesHypoglycemic AgentsdulaglutideExenatideLiraglutideImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • College of Pharmacy, Daegu Catholic University, Gyeongsan, Gyeongsangbuk-do, South Korea.
  • Convergence Research Institute for Biomedical Sciences, Daegu Catholic University, Gyeongsan, Gyeongsangbuk-do, South Korea.

ORCID-Profile: Yun Kim

Förderung

  • Catholic University of Daegu
  • Gyeongsangbuk-do RISE Project

Zitieren

APA

Lee, N., & Kim, Y. (2026). Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes/Metabolism Research and Reviews, 42(4). https://doi.org/10.1002/dmrr.70163

Vancouver

Lee N, Kim Y. Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes/Metabolism Research and Reviews. 2026;42(4). doi:10.1002/dmrr.70163

BibTeX
@article{Lee2026,
  author = {Lee, Nai and Kim, Yun},
  title = {Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  volume = {42},
  number = {4},
  doi = {10.1002/dmrr.70163}
}
Kostenlos starten →